全文获取类型
收费全文 | 9405篇 |
免费 | 588篇 |
国内免费 | 33篇 |
专业分类
耳鼻咽喉 | 47篇 |
儿科学 | 262篇 |
妇产科学 | 156篇 |
基础医学 | 1820篇 |
口腔科学 | 247篇 |
临床医学 | 770篇 |
内科学 | 1889篇 |
皮肤病学 | 293篇 |
神经病学 | 1192篇 |
特种医学 | 308篇 |
外科学 | 813篇 |
综合类 | 42篇 |
一般理论 | 6篇 |
预防医学 | 521篇 |
眼科学 | 142篇 |
药学 | 570篇 |
中国医学 | 19篇 |
肿瘤学 | 929篇 |
出版年
2024年 | 6篇 |
2023年 | 61篇 |
2022年 | 136篇 |
2021年 | 232篇 |
2020年 | 181篇 |
2019年 | 248篇 |
2018年 | 285篇 |
2017年 | 183篇 |
2016年 | 280篇 |
2015年 | 297篇 |
2014年 | 383篇 |
2013年 | 495篇 |
2012年 | 723篇 |
2011年 | 774篇 |
2010年 | 407篇 |
2009年 | 422篇 |
2008年 | 629篇 |
2007年 | 666篇 |
2006年 | 621篇 |
2005年 | 619篇 |
2004年 | 587篇 |
2003年 | 533篇 |
2002年 | 446篇 |
2001年 | 76篇 |
2000年 | 68篇 |
1999年 | 84篇 |
1998年 | 118篇 |
1997年 | 71篇 |
1996年 | 66篇 |
1995年 | 58篇 |
1994年 | 43篇 |
1993年 | 36篇 |
1992年 | 18篇 |
1991年 | 21篇 |
1990年 | 15篇 |
1989年 | 17篇 |
1988年 | 7篇 |
1987年 | 8篇 |
1986年 | 11篇 |
1985年 | 10篇 |
1984年 | 6篇 |
1983年 | 10篇 |
1981年 | 4篇 |
1979年 | 9篇 |
1978年 | 4篇 |
1977年 | 4篇 |
1975年 | 4篇 |
1973年 | 5篇 |
1972年 | 5篇 |
1963年 | 3篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
991.
992.
Evangelia Razis George Pentheroudakis George Rigakos Mattheos Bobos George Kouvatseas Olympia Tzaida Thomas Makatsoris Pavlos Papakostas Maria Bai Anna Goussia Epaminontas Samantas Demetrios Papamichael Ourania Romanidou Ioannis Efstratiou Eleftheria Tsolaki Amanda Psyrri Wendy De Roock Dimitrios Bafaloukos George Klouvas Sabine Tejpar Konstantine T. Kalogeras Dimitrios Pectasides George Fountzilas 《Journal of cancer research and clinical oncology》2014,140(5):737-748
Introduction
Cetuximab is a monoclonal epidermal growth factor receptor (EGFR)-targeting antibody, used in the treatment of colon cancer. KRAS mutation status is strongly predictive of cetuximab efficacy, but more predictive factors are needed for better patient selection. PTEN is a downstream inhibitor of the EGFR pathway and has been evaluated as a predictive factor of cetuximab efficacy in colorectal cancer.Patients and methods
Formalin-fixed paraffin-embedded tumor tissue samples were collected from 226 patients with advanced or metastatic colorectal cancer that had been treated with cetuximab. Clinical information was collected retrospectively from the patients’ medical records. After central evaluation, 147 cases with adequate material were eligible for further evaluation. EGFR and PTEN status was evaluated with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Data were associated with cetuximab treatment outcome. Additional analysis was performed with previously published data on PIK3CA, BRAF and KRAS mutation status and EGFR ligand amphiregulin (AREG) and epiregulin intratumoral mRNA expression levels. PIK3CA mutation status and PTEN protein expression were also analyzed as a single complex parameter, to evaluate the predictive value of PI3K/PTEN axis dysfunction as one entity.Results
Analysis showed a borderline association of overall response rate (ORR) and time to progression (TTP) with EGFR protein overexpression by IHC (p = 0.059 and p = 0.057, respectively) and a positive association of EGFR gain by FISH (found in only five cases) with longer TTP (p = 0.026). No association was found between ORR or TTP and PTEN IHC or FISH status. Comparative analysis with previously published data showed that PTEN protein expression is associated with longer TTP in patients with wild-type (WT) KRAS (p = 0.036) and especially in the ones with elevated AREG levels (p = 0.046), as well as in patients with both KRAS and BRAF WT (p = 0.019). Patients with both PIK3CA WT and PTEN protein expression had significantly longer TTP (p = 0.010) versus all others, in the absence of BRAF and KRAS mutations, a finding which persisted in the KRAS WT/AREG high subgroup (p = 0.046).Conclusions
In this cetuximab-treated colorectal cancer population, EGFR gain was associated with better outcome and PTEN protein expression with longer TTP in KRAS WT, KRAS WT/AREG high and KRAS/BRAF WT subpopulations. Cetuximab efficacy is greater with intact and activated EGFR signaling, without activating mutations of KRAS/BRAF and in the presence of preserved PTEN inhibitory activity upon the PI3K/AKT pathway. These results reflect a solid biological rationale and warrant further evaluation of the predictive role of PTEN in prospective studies. 相似文献993.
994.
995.
Sabine Loeber Anja Kniest Alexander Diehl Karl Mann Bernhard Croissant 《The American journal of drug and alcohol abuse》2013,39(5):584-593
Objectives: In the present study, we investigated whether buprenorphine as a partial μ -opioid receptor agonist is associated with less cognitive impairment than methadone. Methods: Neuropsychological functioning of opioid-dependent patients, previously assigned to methadone (MMP, n = 30) or buprenorphine (BMP, n = 26) maintenance treatment according to their own preference, was compared and dose effects were investigated. Results: MMP and BMP performed equally well on all measures of neuropsychological functioning including the trail making test, the continuous performance test, and a vigilance task. However, patients receiving a higher dose of methadone were impaired in a vigilance task. Conclusions: In a free-choice administration of methadone or buprenorphine, there seems to be no difference in cognitive functioning. Possible explanations are discussed. 相似文献
996.
997.
We report a case of Hirschsprung disease associated with total colonic agenesis and high-type imperforate anus in a newborn girl. The patient also presented with uterus bicornis and a single kidney. The treatment procedure is presented together with a review of literature. The presented combination of pathologies has never been described before. 相似文献
998.
999.
Sabine Scheffler 《Journal of neurology》2001,248(9):822-822
1000.